GlassScriptPhysician profile
Brittany H Case
NPI 1033537154
$17,104.48
in general payments reported to CMS, 2019-2025
83 companies · $3,671 in 2025
The $3,671 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $608 · 2021: $1,370 · 2022: $3,437 · 2023: $3,260 · 2024: $3,855 · 2025: $3,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,029 · Consulting Fee: $940 · Education: $518 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,028.84 |
| Consulting Fee | $940.00 |
| Education | $517.94 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,643.05 | 2019-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $1,632.52 | 2019-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $1,073.87 | 2019-2025 | Erleada, Darzalex, Akeega |
| Astrazeneca Pharmaceuticals LP | $1,052.14 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Celgene Corporation | $809.03 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Lilly USA, LLC | $766.18 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $762.10 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $577.44 | 2019-2023 | Kyprolis, Lumakras |
| Genentech USA, INC. | $529.90 | 2019-2025 | Tecentriq, Polivy, Venclexta |
| Astellas Pharma US INC | $516.32 | 2019-2025 | Padcev, Xospata, Xtandi |
| Daiichi Sankyo INC. | $504.71 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $496.12 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $432.46 | 2021-2025 | |
| Pfizer INC. | $430.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $400.91 | 2019-2025 | Iclusig, Ninlaro, Alunbrig |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.